They discovered that CXCR4 inhibition with AMD3100 attenuated CXCL12 release from cancer-associated fibroblasts (CAFs), and concomitant treatment with an anti-PD-L1 antibody reactivated tumor immune recognition and eradicated PDAC in a murine model [9]. This evidence concerns the gene CXCR4 and neoplasm.